Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the current ratio high or low?
The current ratio of 45.02 is 141% above its 4-year average of 18.72, near the high end of its 4-year range (0.00–45.02).
As of the fiscal period ended Tuesday, June 30, 2026. 89.55% above its 12-month average of 23.75.
Reported quarterly current ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 45.02.
CURRENT RATIO
45.02
CURRENT RATIO AVG TTM
23.75
CURRENT RATIO AVG 3Y
25.04
CURRENT RATIO AVG 5Y
N/A
CURRENT RATIO AVG 10Y
N/A
CURRENT RATIO AVG 15Y
N/A
CURRENT RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+89.55%
CURRENT VS 3Y AVG
+79.79%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.73
median of 864 covered companies
CURRENT VS SECTOR MEDIAN
+1108.71%
vs the sector median at left
Sagimet Biosciences Inc.
Market Cap
$285.25M
Current Ratio
45.02
TTM Avg
23.75
3Y Avg
25.04
5Y Avg
N/A
Market Cap
$285.83M
Current Ratio
6.63
TTM Avg
6.50
3Y Avg
6.00
5Y Avg
4.95
Market Cap
$283.11M
Current Ratio
4.69
TTM Avg
11.27
3Y Avg
11.27
5Y Avg
11.27
Market Cap
$283.11M
Current Ratio
19.48
TTM Avg
1.73
3Y Avg
4.11
5Y Avg
4.35
Market Cap
$281.92M
Current Ratio
31.35
TTM Avg
25.02
3Y Avg
20.04
5Y Avg
16.03
Market Cap
$291.39M
Current Ratio
4.70
TTM Avg
5.10
3Y Avg
7.75
5Y Avg
8.34
Market Cap
$272.01M
Current Ratio
4.85
TTM Avg
6.69
3Y Avg
6.56
5Y Avg
6.64
| NAME | MARKET CAP | CURRENT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Sagimet Biosciences Inc. (SGMT) | $285.25M | 45.02 | 23.75 | 25.04 | N/A |
| Abeona Therapeutics Inc. (ABEO)vs › | $285.83M | 6.63 | 6.50 | 6.00 | 4.95 |
| Standard BioTools Inc. (LAB)vs › | $287.49M | 9.10 | 4.95 | 4.04 | 3.29 |
| BridgeBio Oncology Therapeutics Inc. (BBOT)vs › | $283.11M | 4.69 | 11.27 | 11.27 | 11.27 |
| Indaptus Therapeutics, Inc. (INDP)vs › | $283.11M | 19.48 | 1.73 | 4.11 | 4.35 |
| Fulcrum Therapeutics, Inc. (FULC)vs › | $281.92M | 31.35 | 25.02 | 20.04 | 16.03 |
| Aurora Cannabis Inc. (ACB)vs › | $280.29M | 5.36 | 5.13 | 3.92 | 3.90 |
| Larimar Therapeutics, Inc. (LRMR)vs › | $291.39M | 4.70 | 5.10 | 7.75 | 8.34 |
| Fate Therapeutics, Inc. (FATE)vs › | $272.01M | 4.85 | 6.69 | 6.56 | 6.64 |
| Vanda Pharmaceuticals Inc. (VNDA)vs › | $270.31M | 1.61 | 3.39 | 4.35 | 5.01 |
Current Ratio
45.02
Quick Ratio
45.02
Current Ratio = Current Assets / Current Liabilities
The current ratio measures short-term liquidity — a company's ability to cover current liabilities with current assets. Above 1.0 indicates positive working capital.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | CURRENT RATIO |
|---|---|
| 2026-06-30 | 45.02 |
| 2026-03-31 | 20.34 |
| 2025-12-31 | 22.82 |
| 2025-09-30 | 13.04 |
| 2025-06-30 | 17.55 |
| 2025-03-31 | 20.34 |
| 2024-12-31 | 34.30 |
| 2024-09-30 | 38.41 |
| 2024-06-30 | 29.11 |
| 2024-03-31 | 43.12 |
| 2023-12-31 | 17.09 |
| 2023-09-30 | 20.36 |
| 2023-06-30 | 4.04 |
| 2023-03-31 | 5.12 |
| 2022-12-31 | 6.21 |
| 2022-09-30 | 0.00 |
| 2022-06-30 | 0.00 |
| 2022-03-31 | 0.00 |
